<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638141</url>
  </required_header>
  <id_info>
    <org_study_id>J18118</org_study_id>
    <secondary_id>IRB00179347</secondary_id>
    <nct_id>NCT03638141</nct_id>
  </id_info>
  <brief_title>CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab</brief_title>
  <official_title>The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab
      and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of participants with reduction in tumor burden as defined by mRECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of months until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as determined by number of participants with partial (PR) or complete response (CR) as defined by mRECIST criteria</measure>
    <time_frame>2 years</time_frame>
    <description>PR is defined as &gt;=30% reduction in size of target lesions, whereas CR is defined as disappearance of all target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of months until death from any-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants experiencing drug-related adverse events &gt;= Grade 3 or higher as defined by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Intermediate Stage of Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort A dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).
Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort B dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab IV</description>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort A dose)</arm_group_label>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort B dose)</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab (Cohort A dose)</intervention_name>
    <description>Tremelimumab IV</description>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort A dose)</arm_group_label>
    <other_name>CP-675,206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab (Cohort B dose)</intervention_name>
    <description>Tremelimumab IV</description>
    <arm_group_label>Durvalumab in combination with Tremelimumab (Cohort B dose)</arm_group_label>
    <other_name>CP-675,206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Age 18-75 years

          -  Newly diagnosed with hepatocellular carcinoma

          -  Have measurable disease

          -  Have disease that responds to DEB-TACE

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Body weight &gt;30 kg

          -  Evidence of clinical or radiographic ascites with a score &lt; 7

          -  Patients must have adequate organ function defined by study-specified laboratory
             tests.

          -  Evidence of post-menopausal status or negative pregnancy test

          -  Willing and able to comply with study procedures

          -  Willing to undergo a liver biopsy

        Exclusion Criteria:

          -  Anyone involved with the planning and/or conduct of the study.

          -  Has participated in another investigational study during the last 6 months.

          -  Any concurrent anticancer therapy or received therapy ≤30 days prior to study.

          -  Major surgical procedure at the time of study enrollment or within 28 days prior to
             the first dose of IP.

          -  Have a diffuse HCC (Hepatocellular Carcinoma), vascular invasion or extrahepatic
             tumor.

          -  Main portal vein thrombosis present on imaging.

          -  History of hepatic encephalopathy within past 12 months or require medications to
             prevent or control encephalopathy.

          -  Ascites within 6 weeks prior to study treatment.

          -  Any contraindications for embolization.

          -  Has an active infection such as TB, HIV, hepatitis B or C.

          -  History of another primary malignancy.

          -  History of leptomeningeal carcinomatosis.

          -  History of active primary immunodeficiency.

          -  Any unresolved toxicities from previous anticancer therapy.

          -  Grade ≥2 neuropathy.

          -  History of bleeding disorder.

          -  History or current use of immunosuppressive medications within 14 days prior to study
             medications.

          -  Has an active known or suspected autoimmune disease.

          -  Patients with hypothyroidism.

          -  Any active skin conditions.

          -  History of allogenic organ transplantation.

          -  Significant heart disease.

          -  Patients weighing &lt; 30 kg.

          -  Patients with celiac disease not controlled by diet alone.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Have received a live vaccine within 30 days prior to study drug.

          -  Woman who are pregnant or breastfeeding.

          -  Known allergy or hypersensitivity to the study drug.

          -  Have received durvalumab, tremelimumab, anti-PD-1, anti-PD-L1 or anti-CTLA-4 in a
             prior study.

          -  Unwilling or unable to follow the study schedule for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana De Jesus-Acosta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brad Wilt, RN</last_name>
    <phone>410-614-1816</phone>
    <email>bwilt1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brad Wilt, RN</last_name>
      <phone>410-614-1816</phone>
      <email>bwilt1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ana DeJesus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>DEB-TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

